Subscribe to press release roundup

To regularly receive important releases about Endeavour Vision and portfolio companies

Title *
First name *
Last name *
E-mail *
 
October 28, 2016
New data on EndoStim® therapy for the treatment of gastro-esophageal reflux disease (GERD) presented at United European Gastroenterology Week 2016

 
October 19, 2016
Sophia Genetics, spécialisée dans la bio-informatique, vise les Etats-Unis

 
October 9, 2016
Molecular Partners Presents Data of MP0250 in an All-Comer Phase 1-Study in Solid Tumor Patients and Updates on Phase 2 Studies

 
September 13, 2016
Sophia Genetics and Illumina Sign Co-Marketing Agreement to Speed Adoption of Next-Generation Sequencing (NGS) in Clinical Diagnostics

 
November 26, 2015
Sophia Genetics reaches milestone to become the global leader in precision medicine, connecting over 100 hospitals and laboratories to form the world’s largest clinical genomics community for molecular diagnosis

 
September 2, 2015
Molecular Partners 1H 2015 Release

 
September 1, 2015
CeQur Announces $100 Million Series C Financing

 
September 1, 2015
Symetis announces intention to float on SIX Swiss Exchange

 
August 26, 2015
ReShape Medical, Inc. Completes $38 Million Series D Financing Round Led by HealthCor Partners Management, L.P. and Endeavour Vision SA to Support U.S. Commercialization of ReShape™ Integrated Dual Balloon System Following Recent Approval by the FDA.

 
July 22, 2015
GYNESONICS RAISES $43 MILLION IN EQUITY FINANCING - Endeavour Vision and Abingworth Lead Funding

 
July 21, 2015
Allergan strengthens DARPin development and discovery alliance with Molecular Partners

 
July 7, 2015
First patient enrolled in phase III study of abicipar - Molecular Partners receives USD 15 million milestone payment

 
May 19, 2015
CeQur Announces Publication Of Study Results On PaQ® Insulin Delivery Device To Reduce Barriers To Insulin Therapy

 
May 8, 2015
CeQur Announces Publication of Data Demonstrating PaQ® Insulin Delivery Device Reduces Barriers to Insulin Therapy

 
April 27, 2015
Medtech Investing: Making Late-Stage Deal Pay
 
April 23, 2015
L’étoile montante des medtech suisses

 
March 17, 2015
Molecular Partners reports its results for the Financial Year 2014 ‐  A transformative year for the company

 
March 11, 2015
BIND Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

 
March 10, 2015
BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

 
December 18, 2014
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

 
December 5, 2014
Total offer size of IPO reaches CHF 106.2 million after partial exercise of IPO over-allotment option

 
December 4, 2014
PneumRx Acquired by BTG plc for up to USD 475 Million

 
November 6, 2014
Molecular Partners has successfully priced its IPO post re-launch and lists its shares on SIX Swiss Exchange

 
November 6, 2014
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

 
October 8, 2014
Molecular Partners sets the price range for its IPO at CHF 28 to CHF 35 per share – First trading day expected for 22 October 2014

 
October 6, 2014
Sophia Genetics Adds Cystic Fibrosis Analysis to Clinical Bioinformatics Portfolio

 
September 23, 2014
Molecular Partners launches IPO on SIX Swiss Exchange

 
September 22, 2014
FierceBiotech names Molecular Partners as one of its “Fierce 15” Biotech Companies of 2014

 
September 12, 2014
Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo™, and Launches Product With First Commercial Implantations

 
September 2, 2014
Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing

 
July 8, 2014
Sophia Genetics raises Series B round led by Invoke Capital

 
July 1, 2014
Stage 3 Phase 2 study of DARPin abicipar pegol (previously MP0112) supports progressing to phase III development program

 
June 19, 2014
Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant

 
April 10, 2014
CeQur Appoints Douglas Lawrence Chief Executive Officer

 
April 8, 2014
Epigenetic Cancer Therapy Clears Phase I

 
March 5, 2014
Diabetes Care Publishes Data Demonstrating PaQ® Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes

 
January 8, 2014
CeQur to Present at the 32nd Annual J.P. Morgan Healthcare Conference

 
December 4, 2013
Roche and Molecular Partners enter into alliance to develop new cancer treatments

 
October 28, 2013
Symetis Announces a Symbolic Milestone - the 1000th Patient Implanted with ACURATE TA™

 
October 28, 2013
French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time

 
September 26, 2013
Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI

 
September 24, 2013
Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting

 
September 19, 2013
BIND Therapeutics Announces Pricing of Initial Public Offering

 
September 9, 2013
CeQur SA Closes $27 Million Series B Financing

 
August 27, 2013
BIND Recognized by the World Economic Forum as a Technology Pioneer

 
August 19, 2013
BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer

 
August 12, 2013
BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering

 
August 12, 2013
Symetis announces successful, first time implantation of i ts ACURATE TA™ and ACURATE TF™ TAVI systems in Japan

 
April 3, 2013
Symetis' ACURATE TA(TM) Confirms Superior Results

 
February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

 
April 13, 2010
CeQur SA names Robert O'Holla EVP for Regulatory Affairs

 
Zurich‐Schlieren, July 07, 2015. Molecular Partners AG (ticker: MOLN) today announced that its partner Allergan has initiated phase III clinical trials with abicipar pegol (abicipar) for the treatment of wet age‐related macular degeneration (wet AMD). The event triggered a clinical milestone payment to Molecular Partners of USD 15 million. 

Abicipar is an investigational drug for the treatment of retinal diseases such as wet AMD, a leading cause of blindness in the western world. Abicipar is expected to allow for less frequent dosing compared to currently approved treatments which require monthly or bi‐monthly injections into the eye.  

“We are very pleased to see abicipar moving forward into pivotal development. Abicipar bears the hope to relieve the burden of patients of frequent injections into the eye and to potentially improve their vision compared to current treatments,“ said Christian Zahnd, Chief Executive Officer of Molecular Part ...

more...
© Endeavour Vision SA 2006-2017 Terms & Conditions